Lubiprostone is a Non-Selective Activator of cAMP-Gated Ion Channels and Chloride Channel Protein 2 (Clc-2) Has a Minor Role in its Prosecretory Effect in Intestinal Epithelial Cells

SLC26A6-selective inhibitor identified in a small-molecule screen blocks fluid absorption in small intestine

(2021) Onur Cil et al.   JCI Insight

206: Gastrointestinal symptoms are common in people with cystic fibrosis regardless of gastrointestinal medication usage: Results from GALAXY

(2021) B. Moshiree et al.   Journal of Cystic Fibrosis

208: Effects of tezacaftor/ivacaftor on gut function and transit in cystic fibrosis: A randomized, double-blind, placebo-controlled, crossover trial

(2021) C. Ng et al.   Journal of Cystic Fibrosis

CFTR Modulators: The Changing Face of Cystic Fibrosis in the Era of Precision Medicine

(2020) Miquéias Lopes-Pacheco   Frontiers in Pharmacology

Development and validation of a potent and specific inhibitor for the CLC-2 chloride channel

(2020) Anna K. Koster et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

4,8-Dimethylcoumarin Inhibitors of Intestinal Anion Exchanger slc26a3 (Downregulated in Adenoma) for Anti-Absorptive Therapy of Constipation

(2019) Sujin Lee et al.   JOURNAL OF MEDICINAL CHEMISTRY

Elexacaftor–Tezacaftor–Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele

(2019) Peter G. Middleton et al.   NEW ENGLAND JOURNAL OF MEDICINE

Eicosanoid receptors: Targets for the treatment of disrupted intestinal epithelial homeostasis

(2017) Juan J. Moreno   EUROPEAN JOURNAL OF PHARMACOLOGY

Benzopyrimido-pyrrolo-oxazine-dione CFTR inhibitor (R)-BPO-27 for antisecretory therapy of diarrheas caused by bacterial enterotoxins

(2017) Onur Cil et al.   FASEB JOURNAL

Research and progress on ClC-2

(2017) Hongwei Wang et al.   Molecular Medicine Reports

Gastrointestinal Manifestations of Cystic Fibrosis

(2015) Thomas Kelly et al.   DIGESTIVE DISEASES AND SCIENCES

Prostaglandin D2 regulates human colonic ion transport via the DP1 receptor

(2015) M. Medani et al.   LIFE SCIENCES

Lubiprostone in constipation: clinical evidence and place in therapy

(2015) Nicholas Wilson et al.   Therapeutic Advances in Chronic Disease

Differentiation between human ClC-2 and CFTR Cl− channels with pharmacological agents

(2014) John Cuppoletti et al.   AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY

Revisiting CFTR inhibition: a comparative study of CFTRinh-172 and GlyH-101 inhibitors

(2014) N Melis et al.   BRITISH JOURNAL OF PHARMACOLOGY

Brain white matter oedema due to ClC-2 chloride channel deficiency: an observational analytical study

(2013) Christel Depienne et al.   LANCET NEUROLOGY

Lubiprostone activates CFTR, but not ClC-2, via the prostaglandin receptor (EP4)

(2012) Yohei Norimatsu et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Lubiprostone Targets Prostanoid Signaling and Promotes Ion Transporter Trafficking, Mucus Exocytosis, and Contractility

(2012) Robert L. Jakab et al.   DIGESTIVE DISEASES AND SCIENCES

Lubiprostone for Constipation in Adults with Cystic Fibrosis: A Pilot Study

(2011) Catherine E O'Brien et al.   ANNALS OF PHARMACOTHERAPY

Severe Defects in Absorptive Ion Transport in Distal Colons of Mice That Lack ClC-2 Channels

(2011) Marcelo A. Catalán et al.   GASTROENTEROLOGY

Lubiprostone targets prostanoid EP4 receptors in ovine airways

(2010) AW Cuthbert   BRITISH JOURNAL OF PHARMACOLOGY

Lubiprostone Activates Cl− Secretion via cAMP Signaling and Increases Membrane CFTR in the Human Colon Carcinoma Cell Line, T84

(2010) Mei Ao et al.   DIGESTIVE DISEASES AND SCIENCES

Activation of Intestinal Cl− Secretion by Lubiprostone Requires the Cystic Fibrosis Transmembrane Conductance Regulator

(2009) Marcel J.C. Bijvelds et al.   GASTROENTEROLOGY

Constipation in pediatric Cystic Fibrosis patients: An underestimated medical condition

(2009) H.P.J. van der Doef et al.   Journal of Cystic Fibrosis

A synthetic prostone activates apical chloride channels in A6 epithelial cells

(2008) Hui Fang Bao et al.   AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY

EP4and EP2Receptor Subtypes Involved in Colonic Secretion in Rat

(2008) Ahmed Soliman Mosa et al.   BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY

GW627368X ((N-{2-[4-(4,9-diethoxy-1-oxo-1,3-dihydro-2H-benzo[f]isoindol-2-yl)phenyl]acetyl} benzene sulphonamide): a novel, potent and selective prostanoid EP4 receptor antagonist

(2006) Richard J Wilson et al.   BRITISH JOURNAL OF PHARMACOLOGY